Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

The First Affiliated Hospital with Nanjing Medical University · 2025
ClinicalTrials.gov · Datasets · License: Public Domain · 2025
Open Source ↗
pdras
unresectable metastatic colorectal cancer, microsatellite stable (mss) colorectal cancer (crc), ras-mutant colorectal cancer, sbrt, capeox, bevacizumab, pd-1 inhibitor, ras-mutant, microsatellite stable (mss), unresectable metastatic colorectal cancer (mcrc), interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 843382
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.